Development of a simple HPLC method for the quantitation of vortioxetine in pharmaceuticals using DoE approach
- 17 Downloads
A novel HPLC method was proposed for the quantitation of vortioxetine, which is a new antidepressant drug, in tablets. Separation was performed on a Zorbax Eclipse Plus C18 (3.5 µm particles, 4.6 × 50 mm) column at 35 °C with 1.0 mL/min flow rate and chlorpromazine was selected as internal standard. Box–Behnken design, a design of experiment (DoE) method, was applied to explore the influences of mobile phase pH, acetonitrile content and buffer concentration on chromatographic separation of vortioxetine and chlorpromazine. The optimized conditions were acetate buffer (25 mM, pH:4):acetonitrile (63.5:36.5, v/v). Retention times of chlorpromazine and vortioxetine were 3.8 and 4.6 min, respectively, and a good chromatographic separation was obtained under optimal conditions. Validation studies of the developed method were conducted according to the International Conference on Harmonization (ICH) guideline. The method was linear in the concentration range of 0.5–50 µg/mL. The detection and quantitation limits were 0.080 and 0.264 μg/mL, respectively. Recovery values within 98–102% and relative standard deviation values lower than 2% indicate the precision and accuracy of the method. The method was applied to vortioxetine tablets with no interference.
KeywordsVortioxetine HPLC–DAD Determination DoE Tablet analysis
The authors gratefully acknowledge the support of the Research Council of Anadolu University for the funding of this study (Project no: 1805S211).
Compliance with ethical standards
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- Chen Y, Zhu YL, Qiu CZ, Pan QM, Liu WY, Qiu XJ (2019) A simple HPLC method for the determination of vortioxetine in rabbit plasma and its application to a pharmacokinetic study. Lat Am J Pharm 38(6):1111–1115Google Scholar
- D’Agostino A, English CD, Rey JA (2015) Vortioxetine (Brintellix): a new serotonergic antidepressant. Pharm Ther 40(1):36–40Google Scholar
- Huang Y, Zheng S, Pan Y, Li T, Xu ZS, Shao MM (2016) Simultaneous quantification of vortioxetine, carvedilol and its active metabolite 4-hydroxyphenyl carvedilol in rat plasma by UPLC–MS/MS: application to their pharmacokinetic interaction study. J Pharm Biomed Anal 128:184–190. https://doi.org/10.1016/j.jpba.2016.05.029 CrossRefPubMedGoogle Scholar
- ICH (2005) International Conference on Harmonization. Guideline Q2(R1): Validation of analytical procedures. https://www.ich.org/products/guidelines/quality/quality-single/article/analytical-procedure-development-and-revision-of-q2r1-analytical-validation-copy-1.html. Accessed 15 Apr 2019
- Liu L, Cao N, Ma XL, Xiong KH, Sun LL, Zou QG, Yao LL (2016) Stability-indicating reversed-phase HPLC method development and characterization of impurities in vortioxetine utilizing LC–MS, IR and NMR. J Pharm Biomed Anal 117:325–332. https://doi.org/10.1016/j.jpba.2015.08.028 CrossRefPubMedGoogle Scholar
- Mason RL, Gunst RF, Hess JL (2003) Linear regression with several predictor variables. In: statistical design and analysis of experiments. Wiley, New York, pp 496–534Google Scholar
- Qin M, Qiao HQ, Yuan YJ, Shao Q (2018) A quantitative LC-MS/MS method for simultaneous determination of deuvortioxetine, vortioxetine and their carboxylic acid metabolite in rat plasma, and its application to a toxicokinetic study. Anal Methods 10(9):1023–1031. https://doi.org/10.1039/c7ay02642k CrossRefGoogle Scholar
- Sowa-Kućma M, Pańczyszyn-Trzewik P, Misztak P, Jaeschke RR, Sendek K, Styczeń K, Datka W, Koperny M (2017) Vortioxetine: a review of the pharmacology and clinical profile of the novel antidepressant. Pharmacol Rep 69(4):595–601. https://doi.org/10.1016/j.pharep.2017.01.030 CrossRefPubMedGoogle Scholar